Last updated: May 1, 2026
What is ONIVYDE and where does it sit in current clinical development?
ONIVYDE is irinotecan liposome injection (nanoliposomal irinotecan; “nal-IRI”) marketed by Ipsen. The product’s primary clinical positioning is in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) in combination regimens that depend on prior-line status and biomarker assumptions.
Key approved indications (baseline for market demand)
- Metastatic PDAC (mPDAC): in combination with 5-fluorouracil (5-FU) and leucovorin, for patients after gemcitabine-based therapy.
- Metastatic CRC (mCRC): in combination with 5-FU and leucovorin after prior irinotecan-based regimens for metastatic disease.
(These are the market-defining labels used in uptake and projection models.)
Which trials are currently most relevant to ONIVYDE’s pipeline value?
A complete “current” trials update requires a live registry scan (ClinicalTrials.gov / EU CTR) and an end-to-end mapping of each study’s status, design, endpoints, and readout timing. The instruction set here requires a complete and accurate response; without a real-time trials pull, a definitive clinical-trials update cannot be produced to Bloomberg-grade specificity.
What does the ONIVYDE market look like today?
ONIVYDE demand is driven by:
- Second-line PDAC chemotherapy penetration after gemcitabine
- Subsequent-line sequencing in mCRC where nal-IRI retains a role after irinotecan exposure patterns
- Hospital formulary adoption tied to regimen protocols and reimbursement
Market structure
- Core geography: U.S., EU5 (Germany, France, Italy, Spain, UK), and Japan are the highest-likelihood adoption markets given label history, payer behavior, and oncology spend distribution.
- Customer channel: Specialty oncology centers and large hospital networks where PDAC and mCRC standard-of-care pathways are implemented.
Competitive pressure map (what affects share)
- PDAC is increasingly sensitive to:
- Line 2 regimen shifts driven by newer combinations and molecularly guided care
- Toxicity tolerance and administration preferences (liposomal vs conventional irinotecan)
- mCRC is sensitive to:
- Treatment evolution after standard chemotherapy backbones
- Use of irinotecan re-challenge strategies and biologic combinations
How should ONIVYDE revenue be projected?
A credible forward projection must quantify:
- Addressable patient volumes (incidence, stage at diagnosis, treatment rates, line-of-therapy transitions)
- Share of eligible patients treated with ONIVYDE (formulary and guideline alignment)
- Pricing trends (WAC-to-net dynamics, gross-to-net concessions)
- Lifecycle effects (conversion, competition, and potential label expansions)
A complete, accurate projection is not possible in this response without the underlying numerical inputs and without a current trial status scan that affects expectation-setting (for example: readouts that expand indication breadth or reposition line-of-therapy). The same applies to any scenario-based projection that assumes specific timelines.
What are the decision-grade signals for investors and R&D planners?
Even without a live trial registry extract, the following are the operational signals that typically move ONIVYDE commercial outcomes:
Commercial adoption drivers
- Protocol inclusion: inclusion in regimen pathways at major academic centers and community networks
- Payer coverage stability: consistency of coverage for line-of-therapy eligibility and combination partners
- Administration logistics: infusion scheduling and patient monitoring protocols relative to alternatives
Pipeline value drivers
- Readout timing: whether pivotal or supportive studies complete on schedule
- Endpoint clarity: OS and PFS results that can anchor label or guideline adoption
- Population specificity: whether data support broader eligibility or narrower subgroups
Key Takeaways
- ONIVYDE is a nanoliposomal irinotecan product whose market is primarily tied to PDAC post-gemcitabine and mCRC later-line chemotherapy usage.
- A clinical trials update with readouts, status, and timing requires a live registry pull; producing a complete and accurate update is not possible within this response.
- Forward revenue and volume projections require quantified inputs (patient volumes, line transitions, share assumptions, net pricing, and payer dynamics) and should be rebuilt off a current trial and guideline landscape.
FAQs
-
What is the main therapeutic area for ONIVYDE?
Pancreatic ductal adenocarcinoma and metastatic colorectal cancer chemotherapy settings.
-
What determines ONIVYDE commercial uptake?
Eligibility in line-of-therapy pathways, formulary adoption, payer coverage, and protocol fit in combination regimens.
-
What would most change ONIVYDE’s market trajectory?
Any trial result that shifts line positioning, expands eligible populations, or improves efficacy in a way that moves guideline inclusion.
-
Is ONIVYDE positioned earlier or later in therapy?
It is mainly used in later lines depending on tumor type and prior treatment history, anchored to its established label logic.
-
What inputs are required for an accurate market projection?
Addressable population, treatment-rate and line-transition rates, ONIVYDE share of eligible patients, pricing/net assumptions, and competitive dynamics.
References
[1] Ipsen. ONIVYDE (irinotecan liposome injection) Prescribing Information.
[2] ClinicalTrials.gov. ONIVYDE (nanoliposomal irinotecan) search results and study records.
